Wednesday 28 February 2024
Salisbury Foundation Trust

FOI_7489

Internal Reference Number: FOI_7489

Date Request Received: 13/10/2023 00:00:00

Date Request Replied To: 01/11/2023 00:00:00

This response was sent via: By Email

Request Summary: Breast cancer

Request Category: Companies

 
Question Number 1:
How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

• Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

• Abemaciclib + Fulvestrant

• Alpelisib + Fulvestrant

• Anthracycline (e.g. doxorubicin or epirubicin) as a single agent

• Atezolizumab +Nab-paclitaxel/Paclitaxel

• Capecitabine as a single agent

• Eribulin as a single agent or in combination

• Everolimus + Exemestane

• Fulvestrant as a single agent

• Lapatinib

• Neratinib

• Parp Inhibitors (Olaparib/Talazoparib)

• Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

• Palbociclib + Fulvestrant

• Pembrolizumab

• Platinum (e.g. carboplatin or cisplatin) as a single agent

• Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

• Ribociclib + Fulvestrant

• Sacituzumab Govitecan

• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent

• Taxane and/or Anthracycline in combination

• Trastuzumab as a single agent or in combination

• Trastuzumab emtansine

• Transtuzumab deruxtecan

• Any other active systemic anti-cancer therapy
 
Answer To Question 1:
• Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 8

• Abemaciclib + Fulvestrant <5

• Alpelisib + Fulvestrant <5

• Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0

• Atezolizumab +Nab-paclitaxel/Paclitaxel <5

• Capecitabine as a single agent 7

• Eribulin as a single agent or in combination 0

• Everolimus + Exemestane 0

• Fulvestrant as a single agent 5

• Lapatinib 0

• Neratinib 0

• Parp Inhibitors (Olaparib/Talazoparib) <5

• Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 32

• Palbociclib + Fulvestrant <5

• Pembrolizumab <5

• Platinum (e.g. carboplatin or cisplatin) as a single agent <5

• Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) <5

• Ribociclib + Fulvestrant 0

• Sacituzumab Govitecan <5

• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 8

• Taxane and/or Anthracycline in combination 16

• Trastuzumab as a single agent or in combination 20

• Trastuzumab emtansine 6

• Transtuzumab deruxtecan 5

• Any other active systemic anti-cancer therapy 0
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury NHS Foundation Trust
Trust Values